Physician profile
Sharada Kc
NPI 1306499959
$1,922.80
in general payments reported to CMS, 2019-2025
14 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.50 · 2022: $390 · 2023: $598 · 2024: $727 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,349 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.06 |
| Education | $170.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $536.10 | 2022-2025 | Lifevest |
| Abiomed | $344.90 | 2023-2024 | Impella |
| Medtronic, INC. | $213.75 | 2022-2025 | Crome Dr Mri Surescan, Linq II, Azure Xt Dr Mri Surescan |
| Novartis Pharmaceuticals Corporation | $188.00 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.39 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $149.95 | 2022-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $98.79 | 2022-2024 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $56.65 | 2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $42.52 | 2023-2025 | Camzyos, Eliquis |
| Lexicon Pharmaceuticals, INC. | $34.72 | 2023-2024 | Inpefa |
| Lilly USA, LLC | $24.78 | 2025 | Jardiance |
| Amgen INC. | $22.70 | 2023 | Repatha |
| Pfizer INC. | $21.05 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $13.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharada Kc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.